Biodexa Pharmaceuticals PLC (BDRX) — 6-K Filings

All 6-K filings from Biodexa Pharmaceuticals PLC. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

6-K Filing — Dec 18, 2025
Biodexa Pharma Gets European CTA Approval for Phase 3 Serenta Trial — Nov 3, 2025 Risk: medium
Biodexa Pharmaceuticals PLC announced on November 3, 2025, that it has received approval for its Clinical Trial Application (CTA) in Europe for the Phase 3 Sere
Biodexa Pharmaceuticals Plc Files 6-K Report — Sep 12, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on September 12, 2025, reporting for the period ending June 30, 2025. The company, formerly known as Midatech Pharm
Biodexa Pharmaceuticals Files 6-K — Aug 18, 2025 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 18, 2025. The company, based in Cardiff, United Kingdom, is a pharmaceutic
Biodexa Pharmaceuticals Files July 2025 6-K Report — Jul 31, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on July 31, 2025, reporting for the month of July 2025. The company, formerly known as Midatech Pharma Plc, is base
Biodexa Pharmaceuticals Files July 2025 6-K Report — Jul 15, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on July 15, 2025, reporting for the month of July 2025. The company, formerly known as Midatech Pharma Plc, is base
Biodexa Pharmaceuticals PLC Holds Annual General Meeting — Jun 27, 2025 Risk: low
Biodexa Pharmaceuticals PLC held its Annual General Meeting on June 27, 2025. The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Ki
Biodexa Pharmaceuticals PLC Files 6-K — Jun 13, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on June 13, 2025, reporting on a general meeting of shareholders held on June 11, 2025. The filing indicates that t
Biodexa Pharmaceuticals Files 6-K Report — Jun 11, 2025 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on June 11, 2025. The filing is a report of a foreign private issuer and indicates t
Biodexa Pharmaceuticals Files 6-K Report — Jun 4, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on June 4, 2025, to report information for the month of June 2025. The company, formerly known as Midatech Pharma P
Biodexa Pharmaceuticals Files May 2025 6-K Report — May 30, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on May 30, 2025, reporting for the month of May 2025. The company, formerly known as Midatech Pharma Plc, is a fore
Biodexa Pharmaceuticals Files 2024 Annual Report — May 23, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed its annual report for the year ended December 31, 2024, on May 23, 2025. The company, formerly known as Midatech Pharma Plc, i
Biodexa Pharmaceuticals Plc Files 6-K — May 22, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on May 22, 2025, to report information as a foreign private issuer. The filing indicates the company's principal ex
Biodexa Pharmaceuticals Files 6-K — May 22, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on May 22, 2025, to report information for the month of May 2025. The filing indicates that the company, formerly k
Biodexa Pharmaceuticals PLC Enters Letter Agreements — May 15, 2025 Risk: low
On May 15, 2025, Biodexa Pharmaceuticals PLC entered into letter agreements with certain parties. The company, formerly known as Midatech Pharma Plc, is a pharm
Biodexa Pharmaceuticals Files 6-K Report — May 12, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on May 12, 2025, reporting information for the month of May 2025. The filing indicates that the company, formerly k
Biodexa Pharmaceuticals PLC Announces General Meeting Results — May 2, 2025 Risk: low
Biodexa Pharmaceuticals PLC held a General Meeting on May 2, 2025, where it announced results. The company, formerly known as Midatech Pharma Plc, is based in C
Biodexa Pharmaceuticals Files 6-K, Furnishes Exhibit 99.1 — Apr 17, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on April 17, 2025, to report information as a foreign private issuer. The filing indicates that the company will fi
Biodexa Pharmaceuticals Files Routine 6-K Report — Mar 10, 2025 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on March 10, 2025. This report is for the month of March 2025 and indicates the comp
Biodexa Pharmaceuticals Files 6-K Report — Mar 6, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on March 6, 2025, to report information for the month of March 2025. The company, formerly known as Midatech Pharma
Biodexa Pharmaceuticals Files 6-K Report — Feb 24, 2025 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on February 24, 2025, reporting for the month of February 2025. The company, formerly known as Midatech Pharma Plc,
Biodexa Pharmaceuticals Files 6-K Report — Feb 13, 2025 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on February 13, 2025. The filing is a report of a foreign private issuer for the mon
Biodexa Pharmaceuticals Files Form 6-K — Feb 10, 2025 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on February 10, 2025, to report information for the month of February 2025. The company, formerly known as Midatech
Biodexa Pharmaceuticals Files 6-K Report — Jan 22, 2025 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on January 22, 2025. The filing is a report of a foreign private issuer and indicate
Biodexa Pharmaceuticals Files 6-K Report — Jan 17, 2025 Risk: low
Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on January 17, 2025. The filing is a report of a foreign private issuer for the mont
Biodexa Pharmaceuticals Plc Files 6-K Report — Dec 27, 2024 Risk: low
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on December 27, 2024. The filing is a report of a foreign private issuer for the mon
Biodexa Pharmaceuticals Plc Files December 2024 6-K Report — Dec 4, 2024 Risk: low
Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on December 4, 2024. This report is for the month of December 2024 and indicates the
Biodexa Pharma Complies with Nasdaq Bid Price Rule — Nov 12, 2024 Risk: low
Biodexa Pharmaceuticals Plc (formerly Midatech Pharma Plc) filed a Form 6-K on November 12, 2024, to report compliance with the Nasdaq minimum bid price require
Biodexa Pharmaceuticals Files 6-K Report — Nov 7, 2024 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on November 7, 2024. This report is for the month of November 2024 and indicates the
Biodexa Pharmaceuticals Appoints New Auditor — Nov 1, 2024 Risk: low
Biodexa Pharmaceuticals Plc announced on November 1, 2024, the appointment of PKF Littlejohn LLP as its new auditor, replacing BDO LLP. This change is effective
Biodexa Pharmaceuticals Files 6-K Report — Oct 15, 2024 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on October 15, 2024. The filing is a report of a foreign private issuer and indicates the company files annual repo
Biodexa Pharmaceuticals Files 6-K — Oct 4, 2024 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on October 4, 2024, to report information as a foreign private issuer. The filing indicates that the company will f
Biodexa Pharmaceuticals Plc Files 6-K with Financial Data — Sep 26, 2024 Risk: low
Biodexa Pharmaceuticals Plc filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the six months ended June 30, 2024, a
Biodexa Pharmaceuticals Files 6-K Report — Sep 19, 2024 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 19, 2024. The company, located at 1 Caspian Point, Caspian Way, Cardiff
Biodexa Pharmaceuticals Files 6-K Report — Sep 16, 2024 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on September 16, 2024. The company, incorporated in X0 with its principal executive
Biodexa Pharmaceuticals Files Form 6-K — Aug 30, 2024 Risk: low
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 30, 2024. The company, based in Cardiff, United Kingdom, operates in the P
Biodexa Sells Subsidiary for £1 — Jul 23, 2024 Risk: medium
Biodexa Pharmaceuticals Plc announced on July 23, 2024, that it has entered into a binding agreement to sell its entire issued share capital in its subsidiary,
Biodexa Pharmaceuticals Raises $10M in Direct Offering — Jul 19, 2024 Risk: medium
Biodexa Pharmaceuticals PLC announced on July 18, 2024, that it has entered into agreements for a registered direct offering and a concurrent private placement.
Biodexa Pharmaceuticals Plc Files 6-K Report — Jul 16, 2024 Risk: low
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on July 16, 2024. The filing indicates that the company, based in Cardiff, United Ki
Biodexa Pharmaceuticals PLC: CSO/CMO Departs — Jul 5, 2024 Risk: medium
Biodexa Pharmaceuticals PLC announced the departure of Dmitry Zamoryakhin as Chief Scientific Officer and Chief Medical Officer, effective July 4, 2024. The com
Biodexa Pharmaceuticals Files Form 6-K — Jul 2, 2024 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on July 2, 2024, to report information for the month of July 2024. The filing indicates that the company is a forei
Biodexa Pharmaceuticals Files Routine 6-K — Jun 24, 2024 Risk: low
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on June 24, 2024. This report is for the month of June 2024 and indicates the compan
Biodexa Pharmaceuticals PLC Files 6-K, Incorporates Exhibits — Jun 13, 2024 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on June 13, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (F
Biodexa Pharmaceuticals Files SEC Report — May 28, 2024 Risk: low
Biodexa Pharmaceuticals PLC announced on May 22, 2024, that it has filed a report with the SEC. The company, formerly known as Midatech Pharma Plc, is based in
Biodexa Pharma Induces Warrant Exercise — May 22, 2024 Risk: low
On May 22, 2024, Biodexa Pharmaceuticals PLC entered into letter agreements with certain holders of its outstanding warrants to induce them to exercise their wa
Biodexa Pharmaceuticals PLC Files Form 6-K — May 21, 2024 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on May 21, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (Fi
Biodexa Pharmaceuticals Posts 2023 Annual Report and AGM Notice — May 15, 2024 Risk: low
Biodexa Pharmaceuticals PLC announced on May 15, 2024, that it posted its Annual Report for the year ended December 31, 2023, and the Notice of Annual General M
Biodexa Pharmaceuticals PLC Files 6-K, Incorporates Exhibits — May 15, 2024 Risk: low
Biodexa Pharmaceuticals PLC filed a Form 6-K on May 15, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (Fi
Biodexa Pharmaceuticals Files April 2024 6-K Report — Apr 30, 2024 Risk: low
Biodexa Pharmaceuticals Plc filed a Form 6-K on April 30, 2024, to report its activities for the month of April 2024. This report is incorporated by reference i
Biodexa Pharmaceuticals Files Form 6-K — Apr 26, 2024 Risk: low
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on April 26, 2024. The company, based in Cardiff, United Kingdom, is a pharmaceutica

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX